Fresenius Kabi intros calcitonin salmon injection

Fresenius Kabi is offering calcitonin salmon injection, a calcium regulator, for the treatment of symptomatic Paget’s disease of the bone and hypercalcemia. The drug also is used to treat postmenopausal osteoporosis when alternative treatments are not suitable. Fresenius Kabi Calcitonin Salmon Injection is formulated, filled and packaged in the United States.

Available in 400 I.U./2 ml (200 I.U./ml) vials, the new product adds to the company’s generic injectables portfolio that delivers affordable treatments and a reliable supply for patient care, the company noted.

[Read more: Fresenius Kabi intros generic Tepadina]

“We continue to broaden our portfolio of essential medicines in the U.S. with the launch of Calcitonin Salmon. At Fresenius Kabi, every product addition further underscores our commitment to the ‘supply chain of care’ for patients,” said Arunesh Verma, president of Fresenius Kabi region U.S. and member of the executive leadership team at Fresenius Kabi AG.

[Read more: Fresenius Kabi rolls out epinephrine injection]